Objective:
Primary Objectives:
Part 1
- To evaluate the safety and tolerability of the combination of ONC201 and paclitaxel in patients with platinum refractory or resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Part 2
- To evaluate the objective response rate (ORR) of ONC201 in combination with paclitaxel in patients with platinum refractory or resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
- To evaluate PFS of ONC201 in combination with weekly paclitaxel in patients with platinum refractory or resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Secondary Objectives: (In patients with platinum refractory or resistant epithelial ovarian, fallopian tube or primary peritoneal cancer)
- To evaluate the durability/duration of response (DOR) of ONC201 in combination with paclitaxel
- In Part 2; To evaluate the safety and patient reported tolerability of ONC201 in combination with paclitaxel
- To evaluate the disease control rate (DCR) of ONC201 in combination with paclitaxel
- To evaluate the Cancer Antigen-125 (CA-125) and/or Human Epididymis Factor 4 (HE-4) response of ONC201 in combination with paclitaxel in those patients with one or both of these tumor markers upregulated
- To characterize the PK and PD of ONC201 in combination with paclitaxel
- To obtain preliminary estimates of overall survival (OS) of ONC201 in combination with weekly paclitaxel